← Back to Clinical Trials
Recruiting NCT05729607

NCT05729607 Vertical Soft Tissue Augmentation With CTG vs ADM

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05729607
Status Recruiting
Phase
Sponsor Harvard Medical School (HMS and HSDM)
Condition Implant Complication
Study Type INTERVENTIONAL
Enrollment 28 participants
Start Date 2023-05-26
Primary Completion 2027-02-27

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 99 Years
Study Type INTERVENTIONAL
Interventions
Vertical soft tissue augmentationVertical soft tissue augmentation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 28 participants in total. It began in 2023-05-26 with a primary completion date of 2027-02-27.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative

Eligibility Criteria

Inclusion criteria: * Age ≥ 18 years * Periodontally and systemically healthy * Full-mouth plaque score and full-mouth bleeding score ≤ 20% (measured at four sites per tooth) * Presence of single functional dental implant in the anterior with a PSTD * Implants diagnosed as healthy (Berglundh et al., 2018) Exclusion criteria are: * Contraindications for surgery * Systemic condition (e.g. diabetes mellitus, HIV, cancer, etc) that could compromise wound healing * Patients pregnant or attempting to get pregnant (self-reported) * Untreated periodontitis * Untreated peri-implant mucositis or peri-implantitis (Berglundh et al., 2018) * Smoking, defined as self-reported daily habit. Occasional smokers won't be excluded * History of soft tissue grafting at the implant site within the last 6 months

Contact & Investigator

Central Contact

Lorenzo Tavelli, DDS, MS

✉ lorenzo_tavelli@hsdm.harvard.edu

📞 734-604-4364

Principal Investigator

Lorenzo Tavelli, DDS, MS

PRINCIPAL INVESTIGATOR

Harvard School of Dental Medicine, Boston, USA

Frequently Asked Questions

Who can join the NCT05729607 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Implant Complication. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05729607 currently recruiting?

Yes, NCT05729607 is actively recruiting participants. Contact the research team at lorenzo_tavelli@hsdm.harvard.edu for enrollment information.

Where is the NCT05729607 trial being conducted?

This trial is being conducted at Boston, United States.

Who is sponsoring the NCT05729607 clinical trial?

NCT05729607 is sponsored by Harvard Medical School (HMS and HSDM). The principal investigator is Lorenzo Tavelli, DDS, MS at Harvard School of Dental Medicine, Boston, USA. The trial plans to enroll 28 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology